{"id":7594,"date":"2026-10-23T08:28:22","date_gmt":"2026-10-23T02:58:22","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-23\/"},"modified":"2026-10-23T23:51:52","modified_gmt":"2026-10-23T18:21:52","slug":"alkem-share-price-today-2026-10-23","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-23\/","title":{"rendered":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: ALKEM<\/strong> \u00b7 23 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b94,947.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-1.33%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b95,019.50 \/ \u20b94,877.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b95,013.50<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>54,982<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>23 October 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Alkem Laboratories Ltd. shares fell 1.33% on October 23, 2026, closing at \u20b94,947.00 after trading between an intraday high of \u20b95,019.50 and a low of \u20b94,877.00. The stock opened lower at \u20b94,976.50 following a gap down of 0.74% from its previous close of \u20b95,013.50.<\/li>\n<li>Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.<\/li>\n<li>Trading volume was 0.38 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Alkem Laboratories share price falling on 23 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Alkem Laboratories Ltd. shares fell 1.33% on October 23, 2026, closing at \u20b94,947.00 after trading between an intraday high of \u20b95,019.50 and a low of \u20b94,877.00. The stock opened lower at \u20b94,976.50 following a gap down of 0.74% from its previous close of \u20b95,013.50.<\/p>\n<p class=\"wt-copy\">The broader pharmaceutical sector also faced selling pressure, with the Nifty Pharma benchmark declining by 1.04% and the broader Nifty slipping 0.39%. Alkem&#x27;s move aligns with a broader retracement in healthcare stocks, compounded by its own recent downward momentum that shows a 3.39% decline over the past 5 trading days and an 8.68% drop over the past 20 trading days.<\/p>\n<p class=\"wt-copy\">Company disclosures from October 21, 2026, revealed that Alkem&#x27;s audit committee approved the initiation of a forensic audit by Grant Thornton Bharat LLP regarding an alleged misappropriation of funds by a former employee involving procurement transactions. While this governance update provides notable background context regarding ongoing internal investigations, no direct causality with today&#x27;s intraday price action has been formally established.<\/p>\n<p class=\"wt-copy\">54,982 shares traded by 23 October 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 1.44 lakh shares (0.38 times). The five-day average daily volume was 1.29 lakh shares. Separately, the NSE report for 23 October 2026 showed 28,025 shares delivered, representing 50.97% of that day\u2019s traded volume. The same report recorded 8,341 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector weakness and ongoing governance developments amid low volume<\/strong><\/p>\n<p class=\"wt-copy\">Alkem&#x27;s 1.33% decline occurred alongside broader weakness in the Nifty Pharma sector and below-average trading volume. While the recent announcement of a forensic audit regarding a former employee&#x27;s procurement transactions provides negative sentiment background, the move primarily reflects general sector pressure and continued short-term downward momentum.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Initiation of Forensic Audit<\/div>\n<div class=\"wt-card-date\">21 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.<\/p>\n<p class=\"wt-copy\">Independent forensic reviews highlight governance scrutiny and operational oversight over employee transactions, which can influence investor sentiment regarding internal controls.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Senior Management Appointments<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced the appointment of Mr. Laxmikant Tiwari as Senior Management Personnel for pharmaceutical operations and Mr. Nilesh Vartak for supply chain leadership, both effective October 12, 2026. Both executives bring over two decades of industry experience.<\/p>\n<p class=\"wt-copy\">Leadership additions in operations and supply chain aim to strengthen execution capabilities across manufacturing and distribution channels.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Resignation of Chief Financial Officer<\/div>\n<div class=\"wt-card-date\">24 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Alkem reported that Chief Financial Officer Mr. Nitin Agrawal resigned on July 30, 2026, to pursue new professional opportunities, formally ceasing to hold his senior management position effective September 30, 2026.<\/p>\n<p class=\"wt-copy\">Transitions in key financial leadership roles require close monitoring for continuity in financial reporting and strategic execution.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">16 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated September 16, 2026, titled &quot;Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Management \/ board update<\/div>\n<div class=\"wt-card-date\">12 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Appointment of Mr Nilesh Vartak as Senior Management Personnel of the company effective. October 12, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160911_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">49.70%<\/div>\n<div class=\"wt-note\">51.20% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">10.42%<\/div>\n<div class=\"wt-note\">10.16% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">33.05%<\/div>\n<div class=\"wt-note\">31.56% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.71% on 30 June 2026. This compares with 15.57% on 31 March 2026, a change of +1.14 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 29 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund &#8211; Hdfc Mid-Cap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">57.07 lakh shares \u00b7 4.77%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Multi-Asset Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">42.68 lakh shares \u00b7 3.57%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Large &amp; Midcap Fund<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">23.83 lakh shares \u00b7 1.99%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Motilal Oswal<\/div>\n<div class=\"wt-card-date\">17 August 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Neutral<\/strong><\/span><span><span class=\"wt-label\">Target price<\/span><strong>\u20b95,770.00<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a neutral stance with a target price of \u20b95,770 following Q1 earnings results that featured a profit beat, balancing operational growth against valuation considerations.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JAYANTI SINHA<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 12.38 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 9.04 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SAMPRADA&amp;NANHAMATI SINGH FAMILY TRUST<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 5.50 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND<\/div>\n<div class=\"wt-card-date\">2 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 5.10 lakh shares \u00b7 \u20b95,200.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Developments and findings from the ongoing forensic audit conducted by Grant Thornton Bharat LLP.<\/li>\n<li>Execution and delivery volumes relative to the 20-day average volume of 38% observed today.<\/li>\n<li>Stability and transition progress following recent senior management and CFO changes.<\/li>\n<li>Domestic market performance across acute and chronic pharmaceutical therapeutic segments.<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-22\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.03% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-14\/\">Alkem Laboratories Share Price Today: Why ALKEM Is Falling 0.34% | 14 October 2026 \u2014 14 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-13\/\">Alkem Laboratories in Focus After Senior Management Appointments | 13 October 2026 \u2014 13 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/alkem\/\">More Alkem Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Alkem Laboratories company news?<\/h3>\n<p class=\"wt-copy\">Alkem Laboratories announced that its audit committee approved the appointment of Grant Thornton Bharat LLP to conduct a forensic audit. The investigation follows a recent incident involving suspected financial irregularities and fund misappropriation by a former employee concerning company procurement.<\/p>\n<h3>How strong was Alkem Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">54,982 shares traded, 0.38 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-23\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/alkem-share-price-today-2026-10-23\/\"}, \"headline\": \"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026\", \"description\": \"Alkem Laboratories share price fell 1.33% to \u20b94,947.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-23T02:58:22Z\", \"dateModified\": \"2026-10-23T23:51:45.358309+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/alkem-company-news-2026-10-23.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Initiation of Forensic Audit\",\"summary\":\"Initiation of Forensic Audit\",\"source\":\"NSE\",\"published\":\"21-Oct-2026 21:53:28\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_21102026215316_Reg30Disclosurefinalsigned.pdf\",\"disclosure_text\":\"21st October, 2026 To, The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. Scrip Code: 539523 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. Scrip Symbol: ALKEM Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (\u201cSEBI LODR Regulations\u201d) \u2013 Intimation regarding initiation of Forensic Audit. Dear Sir(s)\/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III thereto, we wish to inform you that the Audit Committee at its meeting today, i.e. 21st October, 2026, has approved the initiation of forensic audit in connection with a recent incident involving alleged misappropriation of funds by a former employee of the Company, for examining the facts and circumstances relating to the incident, determining the root cause and recommending appropriate corrective measures. Details as required under SEBI LODR Regulations read with SEBI Circular No. HO\/49\/14\/14(7)2025- CFD-POD2\/I\/3762\/2026 dated 30th January, 2026 are as follows: Particulars Disclosure Name of the entity initiating the forensic audit Grant Thornton Bharat LLP Reason for initiating the forensic audit To assist in performing a preliminary ESI (electronically stored information) review and market intelligence over procurement done by a former employee of the Company and independently investigate the suspected irregularities in certain transactions affecting the Company, for ascertaining the facts and circumstances and recommending corrective measures. A copy of this disclosure will be made available on the Company\u2019s website in accordance with Regulation 30(8) of the SEBI LODR Regulations. Request you to kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President \u2013 Legal, Company Secretary & Compliance Officer\"},{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"Appointment of Mr Nilesh Vartak as Senior Management Personnel of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"12-Oct-2026 16:09:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160911_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5},{\"summary\":\"Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"12-Oct-2026 16:09:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"recent_news\":[{\"summary\":\"Alkem Laboratories Q1 Result: Net Profit Drops 22% Despite Revenue Growth.\",\"category\":\"Business media\",\"published\":\"2026-08-14T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated September 16, 2026, titled \\\"Press Release Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients.\\\".\",\"category\":\"Press Release\",\"date\":\"16-Sep-2026 11:42:26\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_16092026114204_NeuCenoPressReleasesigned.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 08, 2026, titled \\\"Press Release Alkem Laboratories Limited launches Renocia Exo , India s first patented Ginsenoside Exosome-based hair growth serum\\\".\",\"category\":\"Press Release\",\"date\":\"08-Sep-2026 15:08:39\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_08092026150801_Intimation_signed.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"Appointment of Mr Laxmikant Tiwari as Senior Management Personnel of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"12-Oct-2026 16:09:41\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/ALKEM_12102026160820_Reg30AppointmentofLaxmikantTiwariandNileshVartak_signed.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"promoter_pledge\":{\"summary\":\"An NSE promoter pledge\/encumbrance filing was identified, but the available filing text could not be reduced reliably to a concise current pledge figure.\",\"events\":[{\"summary\":\"le Marg, Worli, Mumbai - 400030 National Stock Exchange of India Limited \\\"Exchange Plaza\\\", 5th Floor, Plot No. C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 051 Symbol: ALKEM Sub: Declaration pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir\/ Madam, Pmsuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeove rs) Regulations, 2011, I, Basudeo N. Singh, promoter of Alkem Laboratories Limited, on behalf of all promoters\/ members of promoters group along with person acting in concert, hereby declare that we have not mad e any encumbrance, directly or indirectly, during the finan cial year 2025-26. The above is for your information and record. Thanking You Yours Sincerely, For and on behalf of Promot er(s) of Alkem Laboratories Limited ~(\\\\),?<:~\/ Basudeo N. Singh Promoter CC: Audit Committee Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013 Maharashtra, India\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"07-Apr-2026 14:30:02\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_06042026134202_Reg_3.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":49.7,\"public_pct\":50.3,\"fii_pct\":10.42,\"dii_pct\":22.63,\"mf_pct\":16.71,\"institutional_pct\":33.05,\"noninst_pct\":17.25,\"mf_scheme_count\":29,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund - Hdfc Mid-Cap Fund\",\"shares\":5706750,\"pct\":4.77},{\"name\":\"Icici Prudential Multi-Asset Fund\",\"shares\":4268472,\"pct\":3.57},{\"name\":\"Sbi Large &amp; Midcap Fund\",\"shares\":2383162,\"pct\":1.99},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":2234434,\"pct\":1.87},{\"name\":\"Dsp Midcap Fund\",\"shares\":2132118,\"pct\":1.78}],\"period\":\"30-JUN-2026\",\"submission_date\":\"09-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1689784_09072026041014_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":51.2,\"previous_fii_pct\":10.16,\"previous_dii_pct\":21.4,\"previous_mf_pct\":15.57,\"previous_institutional_pct\":31.56,\"previous_mf_scheme_count\":30,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Motilal Oswal\",\"rating\":\"Neutral\",\"target\":\"5770\",\"view_summary\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why NDTV Profit\",\"headline\":\"Alkem Labs Gets Target Price Hike After Q1 Beat, But Motilal Oswal Stays Neutral \u2014 Here's Why\",\"published\":\"2026-08-17T07:00:00+00:00\",\"source\":\"NDTV Profit\"}],\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"JAYANTI SINHA\",\"side\":\"Sell\",\"quantity\":\"12,38,220\",\"price\":\"5,200\",\"value\":\"\u20b9643.87 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"ICICI PRUDENTIAL MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"9,03,527\",\"price\":\"5,200\",\"value\":\"\u20b9469.83 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SAMPRADA&NANHAMATI SINGH FAMILY TRUST\",\"side\":\"Sell\",\"quantity\":\"5,50,000\",\"price\":\"5,200\",\"value\":\"\u20b9286.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"HDFC MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"5,09,615\",\"price\":\"5,200\",\"value\":\"\u20b9265.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"DSP MUTUAL FUND\",\"side\":\"Buy\",\"quantity\":\"86,538\",\"price\":\"5,200\",\"value\":\"\u20b945.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"SOCIETE GENERALE\",\"side\":\"Buy\",\"quantity\":\"48,090\",\"price\":\"5,200\",\"value\":\"\u20b925.01 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Nippon India Mutual Fund\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"},{\"deal_type\":\"Block\",\"date\":\"02 Jun, 2026\",\"party\":\"Morgan Stanley Asia Singapore Pte\",\"side\":\"Buy\",\"quantity\":\"48090\",\"price\":\"5,200\",\"source\":\"Public market-data page\",\"value\":\"\u20b925.01 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alkem Laboratories share price fell 1.33% to \u20b94,947.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":7593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Alkem Laboratories Share Price Today: Why ALKEM Is Falling 1.33% | 23 October 2026","_witty_meta_description":"Alkem Laboratories share price fell 1.33% to \u20b94,947.00 today. See why ALKEM is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Alkem Laboratories share price today","_witty_reason_label":"Sector weakness and ongoing governance developments amid low volume","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[143],"class_list":["post-7594","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-alkem"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=7594"}],"version-history":[{"count":4,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7594\/revisions"}],"predecessor-version":[{"id":8400,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7594\/revisions\/8400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/7593"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=7594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=7594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=7594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}